HRP20191864T1 - Imunogeni pripravci protiv bakterije clostridium difficile - Google Patents
Imunogeni pripravci protiv bakterije clostridium difficile Download PDFInfo
- Publication number
- HRP20191864T1 HRP20191864T1 HRP20191864TT HRP20191864T HRP20191864T1 HR P20191864 T1 HRP20191864 T1 HR P20191864T1 HR P20191864T T HRP20191864T T HR P20191864TT HR P20191864 T HRP20191864 T HR P20191864T HR P20191864 T1 HRP20191864 T1 HR P20191864T1
- Authority
- HR
- Croatia
- Prior art keywords
- protein
- immunogenic preparation
- clostridium difficile
- toxin
- isolated
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1411306.2A GB201411306D0 (en) | 2014-06-25 | 2014-06-25 | Immunogenic composition |
| GB201411371A GB201411371D0 (en) | 2014-06-26 | 2014-06-26 | Immunogenic composition |
| EP15733404.6A EP3160500B1 (en) | 2014-06-25 | 2015-06-25 | Clostridium difficile immunogenic composition |
| PCT/EP2015/064324 WO2015197737A1 (en) | 2014-06-25 | 2015-06-25 | Clostridium difficile immunogenic composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20191864T1 true HRP20191864T1 (hr) | 2020-01-10 |
Family
ID=53498986
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20191864TT HRP20191864T1 (hr) | 2014-06-25 | 2015-06-25 | Imunogeni pripravci protiv bakterije clostridium difficile |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20170218031A1 (enExample) |
| EP (2) | EP3160500B1 (enExample) |
| JP (2) | JP6688233B2 (enExample) |
| CN (1) | CN106536544B (enExample) |
| BE (1) | BE1022949B1 (enExample) |
| BR (1) | BR112016030096B1 (enExample) |
| CY (1) | CY1122145T1 (enExample) |
| DK (1) | DK3160500T3 (enExample) |
| ES (1) | ES2749701T3 (enExample) |
| HR (1) | HRP20191864T1 (enExample) |
| HU (1) | HUE045936T2 (enExample) |
| LT (1) | LT3160500T (enExample) |
| MX (1) | MX374380B (enExample) |
| PL (1) | PL3160500T3 (enExample) |
| PT (1) | PT3160500T (enExample) |
| SI (1) | SI3160500T1 (enExample) |
| WO (1) | WO2015197737A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110691609B (zh) * | 2017-03-15 | 2024-04-19 | 诺瓦瓦克斯股份有限公司 | 用于诱导针对艰难梭菌的免疫应答的方法和组合物 |
| CA3102353A1 (en) | 2018-06-19 | 2019-12-26 | Glaxosmithkline Biologicals Sa | Immunogenic composition |
| GB202205833D0 (en) | 2022-04-21 | 2022-06-08 | Glaxosmithkline Biologicals Sa | Bacteriophage |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235877A (en) | 1979-06-27 | 1980-11-25 | Merck & Co., Inc. | Liposome particle containing viral or bacterial antigenic subunit |
| US4436727A (en) | 1982-05-26 | 1984-03-13 | Ribi Immunochem Research, Inc. | Refined detoxified endotoxin product |
| US4866034A (en) | 1982-05-26 | 1989-09-12 | Ribi Immunochem Research Inc. | Refined detoxified endotoxin |
| US4751180A (en) | 1985-03-28 | 1988-06-14 | Chiron Corporation | Expression using fused genes providing for protein product |
| US4935233A (en) | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
| US4877611A (en) | 1986-04-15 | 1989-10-31 | Ribi Immunochem Research Inc. | Vaccine containing tumor antigens and adjuvants |
| WO1988009797A1 (en) | 1987-06-05 | 1988-12-15 | The United States Of America, As Represented By Th | Autocrine motility factors in cancer diagnosis and management |
| US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
| ATE115862T1 (de) | 1989-02-04 | 1995-01-15 | Akzo Nobel Nv | Tocole als impfstoffadjuvans. |
| DE69313134T2 (de) | 1992-06-25 | 1998-02-26 | Smithkline Beecham Biolog | Adjuvantien enthaltende impfstoffzusammensetzung |
| KR100310510B1 (ko) | 1993-03-23 | 2002-07-04 | 장 스테판느 | 3-0-탈아세틸화모노포스포릴지질a를함유하는백신조성물 |
| JP2002514886A (ja) | 1994-10-24 | 2002-05-21 | プロメガ コーポレーション | クロストリジウム・ディフィシル疾患の治療及び予防のためのワクチン及び抗トキシン |
| UA56132C2 (uk) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
| EP0832282A1 (en) | 1995-06-02 | 1998-04-01 | Incyte Pharmaceuticals, Inc. | IMPROVED METHOD FOR OBTAINING FULL-LENGTH cDNA SEQUENCES |
| EP1169456B1 (en) * | 1999-04-09 | 2012-07-11 | Intercell USA, Inc. | Recombinant production of Clostridium difficile Toxin A or Toxin B |
| AU2001251013A1 (en) | 2000-03-28 | 2001-10-08 | Diadexus, Inc. | Compositions and methods of diagnosing, monitoring, staging, imaging and treating colon cancer |
| WO2005004791A2 (en) * | 2002-11-08 | 2005-01-20 | President And Fellows Of Harvard College | Compounds and methods for the treatment and prevention of bacterial infection |
| AU2012349753A1 (en) * | 2011-12-08 | 2014-06-19 | Novartis Ag | Clostridium difficile toxin-based vaccine |
| AR089797A1 (es) * | 2012-01-27 | 2014-09-17 | Merck Sharp & Dohme | Vacunas contra clostridum difficile que comprenden toxinas recombinantes |
| EP2928489B1 (en) * | 2012-12-05 | 2019-02-27 | GlaxoSmithKline Biologicals S.A. | Immunogenic composition |
| GB201223342D0 (en) * | 2012-12-23 | 2013-02-06 | Glaxosmithkline Biolog Sa | Immunogenic composition |
-
2015
- 2015-06-25 BE BE2015/5390A patent/BE1022949B1/fr active
- 2015-06-25 MX MX2016017094A patent/MX374380B/es active IP Right Grant
- 2015-06-25 PL PL15733404T patent/PL3160500T3/pl unknown
- 2015-06-25 DK DK15733404T patent/DK3160500T3/da active
- 2015-06-25 WO PCT/EP2015/064324 patent/WO2015197737A1/en not_active Ceased
- 2015-06-25 US US15/320,190 patent/US20170218031A1/en not_active Abandoned
- 2015-06-25 SI SI201530954T patent/SI3160500T1/sl unknown
- 2015-06-25 EP EP15733404.6A patent/EP3160500B1/en active Active
- 2015-06-25 EP EP19192151.9A patent/EP3636278A3/en not_active Withdrawn
- 2015-06-25 BR BR112016030096-3A patent/BR112016030096B1/pt active IP Right Grant
- 2015-06-25 LT LT15733404T patent/LT3160500T/lt unknown
- 2015-06-25 PT PT157334046T patent/PT3160500T/pt unknown
- 2015-06-25 HU HUE15733404A patent/HUE045936T2/hu unknown
- 2015-06-25 ES ES15733404T patent/ES2749701T3/es active Active
- 2015-06-25 JP JP2016575190A patent/JP6688233B2/ja active Active
- 2015-06-25 CN CN201580039744.7A patent/CN106536544B/zh active Active
- 2015-06-25 HR HRP20191864TT patent/HRP20191864T1/hr unknown
-
2019
- 2019-10-09 CY CY20191101061T patent/CY1122145T1/el unknown
-
2020
- 2020-01-17 JP JP2020005532A patent/JP2020100625A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| PL3160500T3 (pl) | 2020-02-28 |
| CN106536544A (zh) | 2017-03-22 |
| BR112016030096A8 (pt) | 2021-07-06 |
| PT3160500T (pt) | 2019-11-11 |
| EP3636278A2 (en) | 2020-04-15 |
| CA2952118A1 (en) | 2015-12-30 |
| EP3160500A1 (en) | 2017-05-03 |
| EP3160500B1 (en) | 2019-08-21 |
| DK3160500T3 (da) | 2019-11-11 |
| JP2017520573A (ja) | 2017-07-27 |
| BE1022949A1 (fr) | 2016-10-21 |
| US20170218031A1 (en) | 2017-08-03 |
| SI3160500T1 (sl) | 2019-11-29 |
| CY1122145T1 (el) | 2020-11-25 |
| LT3160500T (lt) | 2019-10-25 |
| MX374380B (es) | 2025-03-06 |
| EP3636278A3 (en) | 2020-07-15 |
| MX2016017094A (es) | 2017-05-03 |
| WO2015197737A1 (en) | 2015-12-30 |
| CN106536544B (zh) | 2020-04-07 |
| HUE045936T2 (hu) | 2020-01-28 |
| BE1022949B1 (fr) | 2016-10-21 |
| BR112016030096A2 (pt) | 2017-08-22 |
| JP6688233B2 (ja) | 2020-04-28 |
| JP2020100625A (ja) | 2020-07-02 |
| BR112016030096B1 (pt) | 2023-10-03 |
| ES2749701T3 (es) | 2020-03-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20191291T1 (hr) | Imunogeni pripravak | |
| WO2015024668A3 (en) | Respiratory syncytial virus (rsv) vaccine | |
| EA201890355A1 (ru) | Новые способы индукции иммунного ответа | |
| GEP20217260B (en) | Antibody neutralizing human respiratory syncytial virus | |
| SI2707393T1 (en) | Fusion proteins and combined vaccines comprising protein E and AH haemophilus influenzae | |
| HRP20161608T1 (hr) | Modificirani tuberkulozni antigeni | |
| WO2015181356A8 (en) | Vaccine composition against streptococcus suis infection | |
| PE20190420A1 (es) | Proteinas f de prefusion del virus respiratorio sincicial (vrs) solubles y estabilizadas | |
| HRP20181102T1 (hr) | Cjepiva za hsv-2 | |
| PH12017501370A1 (en) | Bivalent swine influenza virus vaccine | |
| PH12020500569A1 (en) | Influenza virus vaccines and uses thereof | |
| WO2014113490A3 (en) | Immunogenic wt-1 peptides and methods of use thereof | |
| MX376079B (es) | Construcciones de proteina superficial ubicua a2 y usos de las mismas. | |
| MX2016002937A (es) | Vacuna oncologica. | |
| WO2017214596A8 (en) | Compositions and methods for preventing and treating zika virus infection | |
| WO2015107363A3 (en) | Mycobacterial antigen composition | |
| BR112017009790A2 (pt) | anticorpos direcionados ao anti-ang2 e métodos de uso | |
| PE20220960A1 (es) | Proteinas de variantes de secuencias de aminoacidos de cry1da1 activas para lepidopteros | |
| WO2015161267A3 (en) | Humanized and chimeric monoclonal antibodies to cd99 | |
| WO2016061504A3 (en) | Recombinant antibodies that recongnize the c-terminal domains of ebola virus nucleoprotein | |
| HRP20220064T1 (hr) | Zglobno modificirani fragmenti protutijela i postupci za pripravu | |
| EA201892003A1 (ru) | Лечение атопического дерматита собак | |
| MY194448A (en) | Short synthetic peptide for treating diseases and/or conditions related to angiogenesis | |
| WO2012174455A3 (en) | Group a streptococcus multivalent vaccine | |
| MX362058B (es) | Péptido pntx(19) sintético, composición farmacéutica y uso. |